Clascoterone

  • TRADE NAME: Winlevi (Cassiopea)
  • INDICATIONS: Topical treatment of acne vulgaris
  • SYNONYM: Cortexolone 17α-propionate
  • CLASS: Androgen receptor inhibitor
  • HALF-LIFE: Excretion of clascoterone has not been fully characterised in humans.

FDA APPROVAL DATE: 08/26/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

No clinical studies evaluating the drug interaction potential of clascoterone (cream) have been conducted.


No available data to assess drug-associated risk of clascoterone in pregnant women.

Formulated as a cream with cetyl alcohol and other excipients. Local skin reactions (edema, erythema/redness, skin atrophy, stinging/burning, striae rubrea, telangiectasia) were observed during a treatment period with clascoterone cream, and occurred in a similar percentage of subjects treated with the vehicle cream.

Our database has 1 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

OTHER.


Page last updated 04/27/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top